GlassScriptPhysician profile
Shakuntala Patil
NPI 1437599867
$715.81
in general payments reported to CMS, 2019-2025
14 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $28.04 · 2023: $15.45 · 2024: $536 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $687.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $89.72 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $85.55 | 2024 | Shingrix, Trelegy Ellipta |
| Daiichi Sankyo INC. | $71.90 | 2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $69.89 | 2024-2025 | |
| Novo Nordisk INC | $60.11 | 2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $59.75 | 2022-2025 | Airsupra |
| Pfizer INC. | $58.17 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $56.41 | 2024-2025 | Rexulti, Jynarque |
| Lilly USA, LLC | $44.17 | 2024 | Zepbound, Mounjaro, Jardiance |
| Mylan Specialty L.P. | $34.52 | 2024 | Yupelri |
| Abbvie INC. | $28.07 | 2024 | |
| Janssen Pharmaceuticals, INC | $22.66 | 2024 | Xarelto |
| Sanofi Pasteur INC. | $19.44 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.45 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shakuntala Patil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.